Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Rhea-AI Summary

Senseonics (NASDAQ: SENS) announced management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 11, 2026 in Snowbird, Utah.

Investors seeking a meeting are advised to contact their BTIG representatives to request a meeting with Senseonics management.

News Market Reaction

-7.21%

2 alerts

-7.21% News Effect

-$22M Valuation Impact

$280M Market Cap

0.7x Rel. Volume

On the day this news was published, SENS declined 7.21%, reflecting a notable negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $22M from the company's valuation, bringing the market cap to $280M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference edition: 13th Annual Conference date: February 11, 2026

2 metrics

Conference edition 13th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Conference date February 11, 2026 BTIG conference participation in Snowbird, Utah

Market Reality Check

Price: $7.55 Vol: Volume 278,551 vs 20-day ...

low vol

$7.55 Last Close

Volume Volume 278,551 vs 20-day average 452,823 indicates lighter-than-normal trading. low

Technical Price $7.35, trading below the 200-day MA at $9.11 ahead of this conference update.

Peers on Argus

SENS gained 3.67% while key peers were mostly negative: BFLY -0.89%, DCTH -3.95%...

SENS gained 3.67% while key peers were mostly negative: BFLY -0.89%, DCTH -3.95%, RXST -3.25%, TCMD -0.55%, with only PACB +1.98%. This points to stock-specific strength rather than a sector-wide move.

Historical Context

5 past events · Latest: Jan 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 12	Prelim revenue, update	Positive	-1.5%	Record Q4 and 2025 revenue, strong 2026 guidance and business update.
Jan 08	Product integration launch	Positive	+1.4%	First commercial patients using Eversense 365 with twiist AID system.
Nov 10	Conference participation	Positive	+5.3%	Participation in Stifel 2025 Healthcare Conference and investor meetings.
Nov 10	Exchange transfer	Positive	+5.3%	Transfer of stock listing from NYSE American to Nasdaq Global Select Market.
Nov 05	Quarterly earnings	Positive	+0.6%	Q3 2025 revenue growth, improved gross profit, and narrowed net loss.

Pattern Detected

Recent news has generally seen positive reactions: 4 of 5 prior announcements with positive fundamentals or strategic updates led to gains, with one "sell-the-news" dip on strong preliminary revenue.

Recent Company History

Over the last few months, Senseonics has reported strong growth, including preliminary Q4 2025 and full‑year revenue records, expanded guidance, and a move to the Nasdaq Global Select Market. Commercial milestones included the Eversense 365 integration with an AID system and participation in major healthcare conferences. Earnings showed improving revenue and margins. Today’s BTIG conference participation continues the pattern of active investor outreach and visibility around its long‑term implantable CGM platform.

Regulatory & Risk Context

Active S-3 Shelf · $300 million

Shelf Active

Active S-3 Shelf Registration 2025-08-06

$300 million registered capacity

An effective Form S-3 shelf filed on 2025-08-06 allows Senseonics to issue up to $300 million in securities, including a $100 million ATM program with TD Cowen. The shelf remains effective until 2028-08-06, with 0 recorded usages so far, indicating potential future capital-raising capacity alongside possible dilution if utilized.

Market Pulse Summary

The stock moved -7.2% in the session following this news. A negative reaction despite neutral confer...

Analysis

The stock moved -7.2% in the session following this news. A negative reaction despite neutral conference news would fit a pattern where some fundamentally positive updates, such as strong preliminary revenue on Jan 12, 2026, previously saw short-term weakness. With an active S-3 shelf enabling up to $300 million in potential issuance, investors may remain cautious about future dilution. Past events still show that many business milestones have ultimately aligned with constructive price responses.

Key Terms

continuous glucose monitoring (CGM)

1 terms

continuous glucose monitoring (CGM) medical

"long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes"

A continuous glucose monitoring (CGM) system is a small wearable sensor and transmitter that measures a person’s blood sugar levels continuously and sends real‑time readings to a display or smartphone app, reducing the need for finger‑prick tests. Investors care because CGM shifts diabetes care toward ongoing device sales, subscriptions and data services; wider patient adoption, insurance coverage and better accuracy can drive steady revenue and create opportunities for new health products and analytics, similar to moving from one‑off purchases to a subscription service.

AI-generated analysis. Not financial advice.

GERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, Utah.

To request a meeting with Senseonics, investors should contact their BTIG representatives.

About Senseonics

Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com

FAQ

When will Senseonics (SENS) present at the BTIG conference in 2026?

Senseonics management will participate on February 11, 2026 at the BTIG conference. According to the company, the meeting will take place in Snowbird, Utah, as part of the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference schedule.

How can investors request a meeting with Senseonics (SENS) at the BTIG conference?

Investors should contact their BTIG representative to request a meeting with Senseonics management. According to the company, BTIG handles meeting scheduling and investor requests for the February 11, 2026 conference in Snowbird, Utah.

What topics will Senseonics (SENS) management likely cover at the BTIG conference?

Management is expected to discuss Senseonics' long-term implantable CGM systems and business updates. According to the company, the participation centers on MedTech and digital health themes relevant to their continuous glucose monitoring technology.

Where is the BTIG 13th Annual MedTech conference being held for Senseonics (SENS)?

The conference will be held in Snowbird, Utah on February 11, 2026. According to the company, Senseonics management will attend the BTIG event focused on MedTech, digital health, life science, and diagnostic tools.

Will Senseonics (SENS) provide a public webcast or investor materials for the BTIG presentation?

The announcement does not mention a public webcast or materials for the BTIG presentation. According to the company, investors should coordinate with BTIG representatives for meeting access and any available investor engagement at the February 11, 2026 event.